Cargando…

HDAC8 overexpression in mesenchymal stromal cells from JAK2(+) myeloproliferative neoplasms: a new therapeutic target?

Histone deacetylases (HDACs) are involved in epigenetic modulation and their aberrant expression has been demonstrated in myeloproliferative neoplasms (MPN). HDAC8 inhibition has been shown to inhibit JAK2/STAT5 signaling in hematopoietic cells from MPN. Nevertheless, the role of HDAC8 expression in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Teresa L., Sánchez-Abarca, Luis Ignacio, Redondo, Alba, Hernández-Hernández, Ángel, Almeida, Antonio M., Puig, Noemí, Rodríguez, Concepción, Ortega, Rebeca, Preciado, Silvia, Rico, Ana, Muntión, Sandra, González Porras, José Ramón, Cañizo, Consuelo Del, Sánchez-Guijo, Fermín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438642/ https://www.ncbi.nlm.nih.gov/pubmed/28390197 http://dx.doi.org/10.18632/oncotarget.15969

Ejemplares similares

Mesenchymal stromal cells (MSC) from JAK2(+) myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis
por: Ramos, Teresa L., et al.
Publicado: (2017)

MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry
por: L. Ramos, Teresa, et al.
Publicado: (2016)

Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients
por: Muntión, Sandra, et al.
Publicado: (2016)

The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34(+) Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability
por: Preciado, Silvia, et al.
Publicado: (2019)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease
por: Preciado, Silvia, et al.
Publicado: (2023)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Transcriptomic portrait of human Mesenchymal Stromal/Stem cells isolated from bone marrow and placenta
por: Roson-Burgo, Beatriz, et al.
Publicado: (2014)

Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling
por: Roson-Burgo, Beatriz, et al.
Publicado: (2016)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment
por: Carrancio, Soraya, et al.
Publicado: (2011)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
por: Bellido, Mar, et al.
Publicado: (2012)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
por: Anelli, Luisa, et al.
Publicado: (2018)

Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
por: Rao, Raunak, et al.
Publicado: (2020)

Co-administration of human MSC overexpressing HIF-1α increases human CD34(+) cell engraftment in vivo
por: Preciado, Silvia, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms
por: Vladareanu, AM, et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018)

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
por: Tavakoli, Vahid, et al.
Publicado: (2017)

SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
por: Pearson, Stella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cobq3gkgjt3kpkuq36tuqotclu